BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34274316)

  • 1. GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice.
    Pearce AC; Bamford MJ; Barber R; Bridges A; Convery MA; Demetriou C; Evans S; Gobbetti T; Hirst DJ; Holmes DS; Hutchinson JP; Jayne S; Lezina L; McCabe MT; Messenger C; Morley J; Musso MC; Scott-Stevens P; Manso AS; Schofield J; Slocombe T; Somers D; Walker AL; Wyce A; Zhang XP; Wagner SD
    J Biol Chem; 2021 Aug; 297(2):100928. PubMed ID: 34274316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
    Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
    Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
    Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
    Phan RT; Dalla-Favera R
    Nature; 2004 Dec; 432(7017):635-9. PubMed ID: 15577913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
    Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
    J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis of Apt48 inhibition of the BCL6 BTB domain.
    Zacharchenko T; Kalverda AP; Wright SC
    Structure; 2022 Mar; 30(3):396-407.e3. PubMed ID: 34774129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor.
    Okabe S; Fukuda T; Ishibashi K; Kojima S; Okada S; Hatano M; Ebara M; Saisho H; Tokuhisa T
    Mol Cell Biol; 1998 Jul; 18(7):4235-44. PubMed ID: 9632807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.
    Paz K; Flynn R; Du J; Qi J; Luznik L; Maillard I; MacDonald KP; Hill GR; Serody JS; Murphy WJ; Sage PT; Sharpe AH; Miklos D; Cutler CS; Koreth J; Antin JH; Soiffer RJ; Ritz J; Bradner JE; Melnick AM; Blazar BR
    Blood; 2019 Jan; 133(1):94-99. PubMed ID: 30279226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutting edge: T follicular helper cell differentiation is defective in the absence of Bcl6 BTB repressor domain function.
    Nance JP; Bélanger S; Johnston RJ; Takemori T; Crotty S
    J Immunol; 2015 Jun; 194(12):5599-603. PubMed ID: 25957170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
    Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
    Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylation inactivates the transcriptional repressor BCL6.
    Bereshchenko OR; Gu W; Dalla-Favera R
    Nat Genet; 2002 Dec; 32(4):606-13. PubMed ID: 12402037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
    Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
    Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo.
    Dhordain P; Albagli O; Ansieau S; Koken MH; Deweindt C; Quief S; Lantoine D; Leutz A; Kerckaert JP; Leprince D
    Oncogene; 1995 Dec; 11(12):2689-97. PubMed ID: 8545127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCL6 BTB-specific inhibitor reversely represses T-cell activation, Tfh cells differentiation, and germinal center reaction in vivo.
    Cai Y; Poli ANR; Vadrevu S; Gyampoh K; Hart C; Ross B; Fair M; Xue F; Salvino JM; Montaner LJ
    Eur J Immunol; 2021 Oct; 51(10):2441-2451. PubMed ID: 34287839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.
    Cerchietti LC; Ghetu AF; Zhu X; Da Silva GF; Zhong S; Matthews M; Bunting KL; Polo JM; Farès C; Arrowsmith CH; Yang SN; Garcia M; Coop A; Mackerell AD; Privé GG; Melnick A
    Cancer Cell; 2010 Apr; 17(4):400-11. PubMed ID: 20385364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation.
    Pero R; Palmieri D; Angrisano T; Valentino T; Federico A; Franco R; Lembo F; Klein-Szanto AJ; Del Vecchio L; Montanaro D; Keller S; Arra C; Papadopoulou V; Wagner SD; Croce CM; Fusco A; Chiariotti L; Fedele M
    J Biol Chem; 2012 May; 287(22):18308-17. PubMed ID: 22493480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Backbone resonance assignment of the BCL6-BTB/POZ domain.
    Lin LY; Evans SE; Fairall L; Schwabe JWR; Wagner SD; Muskett FW
    Biomol NMR Assign; 2018 Apr; 12(1):47-50. PubMed ID: 28929458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressive BTB/POZ zinc-finger protein ZBTB28 inhibits oncogenic BCL6/ZBTB27 signaling to maintain p53 transcription in multiple carcinogenesis.
    Xiang T; Tang J; Li L; Peng W; Du Z; Wang X; Li Q; Xu H; Xiong L; Xu C; Le X; Wei X; Yu F; Li S; Xiao Q; Luo B; Xiang X; Huang A; Lin Y; Ren G; Tao Q
    Theranostics; 2019; 9(26):8182-8195. PubMed ID: 31754389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
    Cerchietti LC; Yang SN; Shaknovich R; Hatzi K; Polo JM; Chadburn A; Dowdy SF; Melnick A
    Blood; 2009 Apr; 113(15):3397-405. PubMed ID: 18927431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.
    Chang CC; Ye BH; Chaganti RS; Dalla-Favera R
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):6947-52. PubMed ID: 8692924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.